Cutaneous Melanoma Clinical Trial
— NET-DAMOfficial title:
Multicenter, Randomised Study of the Impact of Advanced, Non-invasive Diagnostic Instrumentation for Early Cutaneous Tumor Diagnosis, Clinical-therapeutic Pathways and an Economic-management Perspective
Verified date | March 2021 |
Source | Azienda Ospedaliero-Universitaria di Modena |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The incidence of cutaneous melanoma (MM) is increasing worldwide. The best therapeutical solution for MM is early diagnosis and efforts over the last 50 years have been directed towards early and precise diagnoses. Dermoscopy has improved diagnostic accuracy compared to the naked eye, but is limited by an associated higher number of unnecessary excisions. Reflectance confocal microscopy (RCM) is a novel technique enabling in vivo examination of the skin at cellular-level resolution, with excellent diagnostic accuracy. This study hypothesis is that the systematic application of RCM in the triage and management of patients suspicious for skin cancer, may improve diagnostic accuracy and reduce the number of unnecessary biopsy. Reducing the burden of unnecessary surgery excisions should benefit the health system, both in saving surgical and pathology procedural associated costs and reducing the overwhelming waiting lists for excisions and consequent risk for delayed diagnoses.
Status | Completed |
Enrollment | 3248 |
Est. completion date | March 16, 2020 |
Est. primary completion date | February 28, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patient's with at least 1 unequivocal lesion following standard of care (clinical and dermoscopy evaluations), >= 18 years old Exclusion Criteria: - (i) the presence of an unequivocal aspect of melanoma or of any other malignant skin cancer, - (ii) lesion located on a skin area where reflectance confocal microscopy cannot be performed (for example: skin folds, mucosa, etc.), - (iii) lesion larger than 2 cm in its largest diameter - (iv) lesion where RCM examination is hampered for over the 30% of its surface (for example, for presence of crusting, oozing, erosion, ulceration, etc.). |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Azienda Ospedaliero-Universitaria di Modena |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number needed to excise (NNE) | Measure the number of lesions needed to excise for a cutaneous melanoma diagnosis | 03/2016 - 02/2020 | |
Primary | Early diagnosis | Measure the breslow index of excised lesions | 03/2016 - 02/2020 | |
Primary | RCM diagnostic sensibility and sensitivity | Diagnostic sensibility of RCM in identifying cutaneous melanoma among equivocal lesions suspicious for melanoma (without clear demoscopy criteria for melanoma) | 03/2016 - 02/2020 | |
Secondary | Head and neck pigmented lesions | Diagnostic accuracy of pigmented head and neck lesions where differential diagnosis is difficult to achieve and improper treatments (cryotherapy, laser, radiofrequency). | 03/2016 - 02/2020 | |
Secondary | Diagnostic accuracy of non melanoma skin cancer | Pre-and intra-operative imaging for surgical margins | 03/2016 - 02/2020 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05059444 -
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
|
||
Terminated |
NCT04042480 -
A Study of SGN-CD228A in Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04020809 -
Neoadjuvant Atezolizumab in Cutaneous Melanoma
|
Phase 1 | |
Completed |
NCT03620019 -
Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma
|
Phase 2 | |
Recruiting |
NCT03767348 -
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab
|
Phase 2 | |
Completed |
NCT03628417 -
Confirmatory Trial in the Evaluation of Ca Electroporation for the Treatment of Cutaneous Metastases
|
N/A | |
Withdrawn |
NCT05482074 -
Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2
|
Phase 2 | |
Recruiting |
NCT05970497 -
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
|
Phase 1 | |
Completed |
NCT04551352 -
A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas
|
Phase 1 | |
Recruiting |
NCT05544929 -
A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers
|
Phase 1 | |
Recruiting |
NCT05628883 -
Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma
|
Phase 1 | |
Terminated |
NCT04254107 -
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
|
Phase 1 | |
Recruiting |
NCT04830124 -
Nemvaleukin Alfa (ALKS 4230) Monotherapy in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma - ARTISTRY-6
|
Phase 2 | |
Recruiting |
NCT03699995 -
MoleMapper, Visiomed, and Confocal Microscopy in Screening Participants for Melanoma
|
N/A | |
Recruiting |
NCT06319196 -
Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma
|
Phase 2 | |
Recruiting |
NCT05253872 -
The MELAcare Study: A New Method for Surveillance of Melanoma Patients
|
N/A | |
Recruiting |
NCT04706962 -
TH1902 in Patients With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04792463 -
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
|
||
Completed |
NCT00679289 -
Phase II Study of KW2871 Combined With High Dose Interferon-α2b in Patients With Metastatic Melanoma
|
Phase 2 | |
Recruiting |
NCT05669430 -
A Study of GV20-0251 in Patients With Solid Tumor Malignancies
|
Phase 1 |